Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study

Abstract Clinical trials investigating cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) among patients with cardiovascular and renal disease rarely recruit patients with renal impairment, despite associations with increased risk for major adverse cardiovascular events (MACE). We...

Full description

Bibliographic Details
Main Authors: Sheriza Baksh, Jiajun Wen, Omar Mansour, Hsien-Yen Chang, Mara McAdams-DeMarco, Jodi B. Segal, Stephan Ehrhardt, G. Caleb Alexander
Format: Article
Language:English
Published: Nature Publishing Group 2021-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-95687-z